Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, under-recognised, and under-diagnosed condition that mostly affects older adults.Navigate the site to increase your understanding of the causes of the disease, signs and symptoms, diagnostic tools, and current and emerging treatment options. Visit the Educational Resources section to sign up to a virtual event or watch an expert speaker video.

References:
1. Witteles RM, Bokhari S, Damy T et al.  Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019; 7(8): 709–716  

Click here for Vyndaqel ▼ (tafamidis) prescribing information

PP-VYN-GBR-0401. September 2020